Fertility Suppression on Testosterone Cypionate: Week-by-Week Timeline of What to Expect

How testosterone cypionate switches off sperm production

Testosterone cypionate is an oil-soluble testosterone ester injected deep into the gluteal muscle, labeled at 50 to 400 mg every 2 to 4 weeks, with a half-life of about 8 days after an intramuscular dose [1]. The Depo-Testosterone label describes the mechanism: during exogenous androgen administration, the body's own testosterone release is inhibited through feedback inhibition of pituitary LH, and at large doses also FSH [1]. The same label's adverse reaction list includes oligospermia at high dosages [1].

Sperm production runs on a testosterone concentration inside the testicle that is far above the blood level. In 29 men with normal reproductive physiology, serum testosterone was 1.2% of intratesticular testosterone at baseline [2]. Suppress the pituitary, and that reservoir inside the testicle is what falls.

Weeks 1 to 3: the pituitary signal drops

The clearest early measurements come from a randomized study of 29 men with normal reproductive physiology, who received 200 mg testosterone enanthate weekly plus either placebo injections or hCG at 125, 250 or 500 IU every other day [2]. Enanthate and cypionate are both oil-soluble esters absorbed slowly from the injected oil depot [1]. At three weeks, the testosterone-plus-placebo group had LH at 5% of baseline and FSH at 3%, and intratesticular testosterone had fallen 94%, from 1234 to 72 nmol/L [2]. Adding hCG alongside the testosterone raised intratesticular testosterone back in a dose-dependent way [2].

The study used enanthate and measured at baseline and at three weeks, so it shows how far the axis had fallen by that point but not the week-by-week course.

What sperm counts can look like during testosterone use

The published sperm data on testosterone users are mostly snapshots taken after suppression is already established. In one series, all 49 men referred for fertility had azoospermia or severe oligospermia under 1 million sperm per mL while taking exogenous testosterone [4]. In another, 66 men presented with infertility after testosterone use, and the azoospermic men recovered less often than the cryptozoospermic men: 64.8% versus 91.7% reached a total motile count above 5 million within 12 months of stopping testosterone and starting treatment [6].

Both series show that suppression to zero or near-zero is a real outcome, in men who came to fertility clinics. The Depo-Testosterone label states the same possibility in general terms, listing oligospermia at high dosages [1].

Does suppression last as long as injections continue?

The label describes ongoing inhibition of the body's own testosterone release through pituitary feedback for as long as exogenous androgen is given [1]. The label also lists testicular atrophy, subfertility and infertility among reactions reported in men who abuse anabolic steroids at doses above those recommended [1].

After the last injection: month-by-month recovery

The largest recovery dataset is an integrated analysis of 30 hormonal male contraceptive studies: 1,549 healthy men with normal testosterone production, aged 18 to 51, on androgen or androgen-progestin regimens. These were not men with hypogonadism on replacement doses [3]. The median time for sperm concentration to return to 20 million per mL was 3.4 months. Recovery to that threshold was 67% by 6 months, 90% by 12 months, 96% by 16 months and 100% by 24 months. Recovery was faster with shorter-acting testosterone preparations, shorter treatment, older age and a higher baseline sperm count [3].

A second dataset followed 66 men treated for infertility after testosterone use: 46 (70%) reached a total motile count above 5 million within 12 months of stopping testosterone and starting high-dose hCG plus a selective estrogen receptor modulator. Older age and longer duration of testosterone use both correlated with slower recovery at 6 and 12 months [6]. Thirty percent of that group had not reached the threshold at 12 months [6].

If recovery is slow: hCG and SERM treatment

In a case series of 49 men with azoospermia or severe oligospermia while on exogenous testosterone, treatment with hCG 3,000 units subcutaneously every other day plus clomiphene, tamoxifen, anastrozole or recombinant FSH brought sperm back or improved counts in 47 men (95.9%). The average time to return of spermatogenesis was 4.6 months, with a mean first density of 22.6 million per mL, and recovery did not differ significantly by the type of testosterone used [4]. This was a retrospective series without a control group, so it cannot show how much of the improvement came from the drugs.

A separate 3-week randomized study tested the maintenance side of the question. In men on 200 mg testosterone enanthate weekly, hCG at 125, 250 or 500 IU every other day kept intratesticular testosterone near baseline; the 500 IU dose left it 26% above baseline and the 250 IU dose left it 7% below [2]. That study measured intratesticular testosterone during testosterone use, not sperm recovery after stopping.

SERMs and aromatase inhibitors have also been studied in male infertility. A review of that literature found some evidence that, in a subset of infertile men with hypogonadism or a low testosterone-to-estradiol ratio, these drugs can raise serum testosterone and occasionally improve the infertile state [7].

Before the first injection

The Endocrine Society's 2018 guideline recommends against starting testosterone therapy in men who plan to have children in the near term [5].